Skip to content
value.today

Ray Therapeutics, Inc.

🇺🇸 San Diego, California, USABiotechnologyFounded 2021
Total raised
$20 M
2 rounds on record
Latest round
$14 M
May 2023
First round on record
May 2021
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Ray Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2023$14 MNo. 2$10 to $50 million

Ray Therapeutics, Inc.: Raise no. 2, May 2023

Investors in this round

13 investors had bought by the notice of May 26, 2023: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Ray Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$14 M of $100 M offered; $86 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Paul Bresge · Executive Officer, Director
  • Sean Ainsworth · Executive Officer, Director
  • Dmitry Kuzmin · Director
  • Gary Abrams · Director
  • Hannah Chang · Director
  • Raymond Camahort · Director
  • Tiba Aynechi · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Paul Bresge, Chief Executive Officer. Source: SEC Form D, newest notice filed May 26, 2023. Read the notice at the SEC.

equitySEC
May 2021$6 MNo. 1$2 to $10 million

Ray Therapeutics, Inc.: Raise no. 1, May 2021

Investors in this round

15 investors had bought by the notice of Apr 5, 2022: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Ray Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in California

People named in the notice

  • Andrew Howard · Executive Officer
  • Paul Bresge · Executive Officer, Director
  • Sean Ainsworth · Executive Officer, Director
  • Cameron Gallagher · Director
  • Dmitry Kuzmin · Director
  • Gary Abrams · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Paul Bresge, Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 5, 2022. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Ray Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (May 2023).

    SEC Form D · May 2023

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · May 2023

That is all the official record says: Ray Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

1 named in official filings. Open an investor to see everything it has backed.

Investors in Ray Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Franklin Biotechnology Discovery FundFund or asset manager$4 Mheldnot statedHolds shares (fund report, Jul 2026)SEC Form N-PORT

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 15 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Ray Therapeutics, Inc.
NameRoleNamed in
Paul BresgeExecutive officerMay 2023
Sean AinsworthExecutive officerMay 2023
Andrew HowardExecutive officerApr 2022
Dmitry KuzminDirectorMay 2023
Gary AbramsDirectorMay 2023
Hannah ChangDirectorMay 2023
Paul BresgeDirectorMay 2023
Raymond CamahortDirectorMay 2023
Sean AinsworthDirectorMay 2023
Tiba AynechiDirectorMay 2023
Cameron GallagherDirectorApr 2022